Gelonghui, April 23 | According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 5 million shares by Executive Director Xie Chengrun on the market at an average price of HK$239 per share, involving approximately HK$116.19,500.
After the increase in holdings, Tse Chengyun's latest shareholding was 4,055,000,000 shares, and the shareholding ratio increased from 21.54% to 21.57%.
